A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer

NCT00022672 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

208

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: trastuzumab (Herceptin®)
DRUG: anastrazole (Arimidex®)

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]